SHORT COMMUNICATIONWeight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 geneHsiao, Dun-Jena; Wu, Lawrence Shih-Hsinc; Huang, Shih-Yib; Lin, EugenecAuthor Information aCollege of Public Health and Nutrition bSchool of Nutrition and Health Sciences, Taipei Medical University cVita Genomics Inc., Wugu Shiang, Taipei, Taiwan Correspondence to Dr Eugene Lin, 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan Tel: +886 2 8976 9123 x7751; fax: +886 2 8976 9523; e-mail: [email protected] Dun-Jen Hsiao and Lawrence Shih-Hsin Wu contributed equally to this study Received 28 April 2009 Accepted 6 July 2009 Pharmacogenetics and Genomics: September 2009 - Volume 19 - Issue 9 - p 730-733 doi: 10.1097/FPC.0b013e3283307cf1 Buy Metrics Abstract The relationship between weight reduction after sibutramine treatment and a single nucleotide polymorphism, rs5443 (C825T), in the guanine nucleotide binding protein β polypeptide 3 (GNB3) gene is currently inconsistent. In this study, we aimed to reassess whether the GNB3 rs5443 single nucleotide polymorphism could influence weight reduction and body composition change under sibutramine therapy in 131 obese Taiwanese patients. By comparing the sibutramine and placebo groups with analysis of covariance, our data showed a strong effect of sibutramine on weight reduction (7.4±1.4 vs. 3.4±1.2 kg; P<0.001) and on body fat percentage loss (4.2±0.1 vs. 2.1±0.1%; P<0.001) in the combined TT+TC carriers. In contrast, sibutramine caused no significant additional effect on weight loss (P = 0.078) or on body fat percentage loss (P = 0.441) in homozygous C allele carriers. © 2009 Lippincott Williams & Wilkins, Inc.